✦ LIBER ✦
Disease Flare after Tyrosine Kinase Inhibitor Discontinuation in Patients with EGFR-Mutant Lung Cancer and Acquired Resistance to Erlotinib or Gefitinib: Implications for Clinical Trial Design
✍ Scribed by Chaft, J. E.; Oxnard, G. R.; Sima, C. S.; Kris, M. G.; Miller, V. A.; Riely, G. J.
- Book ID
- 111955093
- Publisher
- American Association for Cancer Research
- Year
- 2011
- Tongue
- English
- Weight
- 338 KB
- Volume
- 17
- Category
- Article
- ISSN
- 1078-0432
No coin nor oath required. For personal study only.